Collaboration News: Breaking Collaboration News, Comments and Articles. - Page: 5

Corgenix Medical Collaborates With Eli Lilly To Develop Diagnostic Technology

INDIANAPOLIS (dpa-AFX) - Corgenix Medical Corp. (CONX.OB) announced that it has entered into a collaboration agreement with Eli Lilly and Co.(LLY) to develop diagnostic technology in support of a ...

Modern Medical Introduces Opioid Abuse Solution to the Workers' Compensation Industry

LEWIS CENTER, Ohio, May 22, 2013 /PRNewswire/ -- Modern Medical announced today the nationwide rollout of Opioid Defense Manager™ (ODM).  Launched in November 2012 in a test phase, ODM is Modern Medical's revolutionary managed care program to stop the rising opioid abuse in the workers' compensation industry.  ODM is a proactive, customized program designed to protect employee...

The Nordic Model: “Co-Creating” your Way to Better Health Outcomes

Précis:  Petteri Jarkka, Customer Engagement Manager at Janssen Nordic, talks to eyeforpharma about how the company is responding to recent calls for a ‘beyond the pill’ approach, and how they’...

UCB, IBM collaborate to personalize care for epilepsy patients

UCB, a Belgium-based global biopharmaceutical company focused on diseases of the immune system and central nervous system, and IBM have completed the initial phase of a project designed to harness the power of analytics to help healthcare providers d...

Corgenix Announces Diagnostic Development Agreement with Lilly

-- Companies to focus on potential companion diagnostic opportunity -- Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, announced today that it has entered into a collaboration agreement with Eli Lilly and Company (NYSE: LLY) to develop diagnostic technology in support of a Lilly oncology pipeline...

Elan announces transactions to transform the company

Elan, a biotechnology company based in Ireland, announced a series of transactions designed to decisively transform and advance the company. Upon shareholder approval, the totality of these strategically driven decisions, in addition to the Theravanc...

Nordion, Navidea Biopharmaceuticals ink contract manufacturing agreement

Nordion, a provider of products and services to the global health science market, has signed a contract manufacturing agreement with Navidea Biopharmaceuticals, a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals. Nordion...

Marcia Cross Stars In New PSA About Prostate Cancer With The Safeway Foundation And Stand Up To Cancer

LOS ANGELES and NEW YORK, May 22, 2013 /PRNewswire-USNewswire/ -- The Safeway Foundation and Stand Up To Cancer (SU2C), a program of the Entertainment Industry Foundation (EIF), have teamed up to develop a print, radio and digital public service announcement featuring actress and SU2C Ambassador Marcia Cross. The PSA is designed to increase awareness for the fight against prostate cancer...

Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration

New York, NY and Troy, NY (PRWEB) May 22, 2013 The Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute today announced an affiliation agreement to collaborate on educational programs, research, and development of new diagn...

Par Pharmaceutical Begins Shipment of Generic Atacand®

WOODCLIFF LAKE, N.J., May 22, 2013 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has entered into an exclusive U.S. supply and distribution agreement with AstraZeneca to distribute the authorized generic version of AstraZeneca's Atacand® (candesartan cilexetil).  Par has begun shipping 4 mg, 8 mg, 16 mg and 32 mg strengths of candesartan cilexetil tablets.
...

LipoScience's Vantera® Clinical Analyzer To Provide Hospitals And Physicians With Lipoprotein Analysis For Cardiovascular Disease Management

RALEIGH, N.C., May 22, 2013 /PRNewswire/ -- LipoScience, Inc.,  (NASDAQ:  LPDX) a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care, today announced availability of NMR lipoprotein particle testing using the Vantera® Clinical Analyzer through Mayo Medical Laboratories. NMR lipoprotein...

Hygie is launching a new website!

BROSSARD, QC, May 22, 2013 /PRNewswire/ - Hygie® is launching a new website www.hygie.com . With our new modern, user-friendly site, hygiene solutions for healthcare and home settings are just a few clicks away. The site is divided into two separate sections to meet the needs of two distinct audiences: healthcare professionals and consumers at home. We provide advice and expertise to op...

DePuy Pinnacle Lawsuit Update: Federal Court Orders DePuy to Produce Data from Sales Practices Investigation, Rottenstein Law Group LLP Reports

The firm is actively filing DePuy Pinnacle lawsuits on behalf of individuals who allegedly suffered metallosis, premature device failure and other serious complications related to the metal-on-metal hip implant. (PRWEB) May 22, 2013 Pretrial proceedings for federal DePuy Pinnacle lawsuits are progressing. On May 15 a judge for the Pinnacle multidistrict litigation ordered Johnson & Johnson’...

Celsion Announces Issuance of Additional Patents Covering ThermoDox® Technologies

LAWRENCEVILLE, N.J., May 22, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced today that its proprietary patent application, "Method of Storing Nanoparticle Formulations," has now been granted in the four largest markets for liver cancer globally:  China, Japan, South Korea and most recently Taiwan.  Celsion holds an exclusive license agreement with Duke University...

GWU launches Avance Center for the Advancement of Immigrant/Refugee Health

Today the George Washington University School of Public Health and Health Services announced the launch of the Avance Center for the Advancement of Immigrant/Refugee Health, a collaboration between SPHHS, the Maryland Multicultural Youth Centers, the...

Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye

SOUTH SAN FRANCISCO, Calif., May 22, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the clinical advancement of three programs in development. The first program is a wholly-owned topical ophthalmic formulation of a JAK/SYK inhibitor, R348, being developed by Rigel as a treatment for dry eye disease.  The other two programs are aimed at oncology targets and are...

Soligenix Announces Issuance of US Patent for its ThermoVax™ Technology

PRINCETON, N.J., May 22, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that the US Patent and Trademark Office granted patent 8,444,991 entitled "Method of Preparing a...

Talking Dog Research: MIT Startup GeriJoy and Pace University Collaborate to Determine Clinical Efficacy of Virtual Companions for Senior Care

GeriJoy provides virtual talking dogs as companions for the elderly. Following anecdotal evidence of GeriJoy's senior companionship service improving mental health and even rolling back Alzheimer's, Pace University will begin a research study this summer to determine the clinical efficacy of the GeriJoy Companion system. New York, NY (PRWEB) May 22, 2013 Research shows that loneliness is...

Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team

Express Diagnostics’ Australian and New Zealand distributor of DrugCheck® onsite testing devices, Royal Medical Supplies, has signed an agreement to sponsor V8 Supercar team Erebus Motorsport. The agreement involves each car of the team displaying the Royal Medical logo in Australian racing events. Blue Earth, MN (PRWEB) May 22, 2013 Express Diagnostics Int’l, Inc. (EDI), and Royal Medic...

CEO Per Wickstrom of Best Drug Rehabilitation Interviews PR Networks’ John Graves at Imagination Heals Event

Per Wickstrom, the CEO of holistic treatment facilities including Best Drug Rehabilitation, recently interviewed PR Networks’ CEO and President John Graves at the recent Imagination Heals event in Los Angeles. (PRWEB) May 22, 2013 Best Drug Rehabilitation’s CEO Per Wickstrom, who believes that compassionate, confidential and specialized one-on-one counselling with a licensed counselor is an e...

Curie-Cancer and Roche strengthen partnership to fast-track the development of new molecules

Curie-Cancer and Roche build on four years partnership by increasing translational research programs, speeding up development of new cancer treatments   Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities, and the Roche Institute for Research and Translational Medicine are strengthening their collaborative efforts. In 2009, the Institut...

UK-Norwegian collaboration aims to develop a new living skin equivalent testing model for testing inflammatory responses.

Epistem, the UK biotechnology and personalized medicine company with expertise in skin biology and delivery of dermatological testing services, and ScandiDerma, a Norwegian company with expertise in developing new dermatological ingredients from biom...

QuantuMDx and Genome Institue of Singapore announce collaboration to develop Asia-specific assays on QuantuMDx's Q-POC™

First test to direct treatment of chronic leukemia and lung cancer.A*STAR’s Genome Institute of Singapore (GIS) has signed an agreement with QuantuMDx (QMDx), a UK-based biotech developing handheld diagnostics and whole genome sequencing devi...

Life Science Talent Shines at new UK Skills Awards. Apprentices, graduates, employers, providers and leaders in the spotlight on skills

250 guests gathered at London’s Grand Connaught Rooms to witness the inaugural UK Life Science Skills Awards, organised by Cogent, the strategic skills body for the science industries.The event, which took place on Thursday 16th May, saw 30...

OncoGenex Announces Multiple 'Trials in Progress' Presentations at the 2013 ASCO Annual Meeting

BOTHELL, Wash. and VANCOUVER, British Columbia, May 22, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), a leader in the development of novel therapeutics to target mechanisms of treatment resistance in cancer, today announced that four trials of its investigational compounds, custirsen and OGX-427, will be presented as "Trials in Progress" posters at the 49th Annual Meeti...